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There are several invasive and noninvasive methods available to the clinical researcher for the assessment of endothelial function.
The ﬁrst investigations in humans involved invasive pharmacological vascular function testing, which have been used to gain a
detailed understanding of the mechanisms involved in the pathogenesis of endothelial dysfunction and atherosclerosis as well as
novel targets for intervention. Techniques for endothelial function testing have evolved over time from these invasive methods,
which, by their nature, are restricted to small studies in the research laboratory, to more standardized noninvasive methods, which
are suitable for use in large prospective cohort studies and clinical trials. This paper describes currently available methods for
assessment of endothelial function and their potential application in cardiovascular research and clinical practice.
1.Introduction
The single-cell monolayer that lines the vascular system, the
endothelium, is responsible for homeostasis of the blood
vessels. It releases a number of factors that play a role in
the regulation of vascular tone, the inhibition of platelet
aggregation, and the adhesion of leukocyte. Disturbances
in these processes cause endothelial activation and dys-
function, characterized by a decrease in the availability
of the endothelium-derived vasodilator nitric oxide (NO)
and the activation of vasoconstrictors such as endothelin-1
and angiotensin II. In combination with the expression of
prothrombotic, proinﬂammatory, and adhesion molecules,
this initiates an environment favourable to the development
of atherosclerotic lesions. These lesions eventually develop
into plaques, which can gradually progress to luminal
obstruction and ischemia, or destabilize and rupture result-
ing in acute events such as myocardial infarction and stroke.
Endothelial dysfunction is the earliest clinically identiﬁable
event in the process of cardiovascular disease.
2. Rationale for Testing Endothelial Function
Furchgott and Zawadzki were the ﬁrst to demonstrate that
endothelial cells were required for smooth muscle relaxation
to occur in response to acetylcholine administration in
rabbit aorta [1]. Nitric oxide was later identiﬁed as the
substance responsible for this relaxation [2]. Based on this
and other works, Ludmer et al. were the ﬁrst to show
that acetylcholine caused vasoconstriction in atherosclerotic
arteries and vasodilatation in healthy vessels in the human
coronary circulation during cardiac catheterization [3].
Assessing changes in forearm blood ﬂow in response to
pharmacological probes allows a more detailed exploration
of resistance vessel function, but these invasive studies
are only appropriate for use in small study cohorts. In
1992, Celermajer et al. developed a noninvasive method for
assessing endothelial function in the conduit arteries of the
peripheral circulation [4]. This technique uses a period of
forearm ischemia followed by reactive hyperemia to increase
brachial arterial blood ﬂow and, consequently, shear stress.
This induces endothelial release of NO which mediates2 Cardiology Research and Practice
smooth muscle relaxation and vasodilatation of the brachial
artery [5]. Since then other techniques have been developed
that either employ reactive hyperemia or administration of
drugs to stimulate the endothelium. Endothelial vasodilator
function in the peripheral circulation has been shown to be
related to coronary endothelial function and cardiovascular
risk factors such as dyslipidemia, smoking, and diabetes and
to be predictive of cardiovascular events [6–10].
3. Methods for Assessing Endothelial Function
Several invasive and noninvasive methods have been devel-
oped for the assessment of endothelial function. No sin-
gle method is the perfect test, and a combination may
be required for a comprehensive evaluation of vascular
endothelial biology.
3.1. Invasive Assessment of Endothelial Function. The orig-
inal clinical investigations of endothelial vasomotor func-
tion assessed the coronary circulation. Changes in the
epicardial and microvascular responses to endothelium-
dependent pharmacological agents are measured during car-
diaccatheterizationusingquantitativecoronaryangiography
and the Doppler ﬂow-wire techniques. Preserved epicardial
coronary endothelial function is characterized by vasodi-
latation in response to acetylcholine. Constriction of the
vessel is indicative of the smooth muscle response to direct
muscarinic receptor stimulation overwhelming the absent or
depressed dilation that follows from reduced bioavailability
of endothelial NO [11]. the use of this technique is realisti-
cally restricted to individuals in the more advanced stages of
arterial disease as it should only be carried out in those with
clinical indications for cardiac catheterization. However,
coronary vascular function testing has provided important
insights into the eﬀects of atherosclerosis and its risk factors
on coronary regulatory physiology and risk stratiﬁcation as
wellasdemonstratedthepotentialreversibilityofendothelial
dysfunction in response to treatments such as statins and
ACE-inhibitors [12–14].
Forearm resistance vessels can be studied using venous
occlusion plethysmography to assess changes in forearm
blood ﬂow (FBF) in response to pharmacological agents.
This technique provides its own control by using the
contralateral arm, permitting adjustments to be made for
systemic inﬂuences that aﬀect basal ﬂow and blood pressure
in the noninfused arm. The majority of studies measure per-
centage diﬀerences in FBF and vascular resistance between
experimental and control arms following administration
of endothelium-dependent and endothelium-independent
agonists. Evaluation of the contribution of NO to vasomotor
regulation can be made using eNOS antagonists such as
L-NMMA. This technique can be used in healthy controls
as well as patients, allowing the study of the endothelium
from early in the disease process. It also allows other
vasomotor pathways in addition to NO to be evaluated.
However, it remains an invasive technique which limits its
repeatability and also restricts its use to small studies. Also,
the clinical relevance to atherosclerosis has been questioned,
as microvascular pathophysiology may not necessarily reﬂect
changes in the conduit arteries in which the plaques develop.
3.2. Noninvasive Methods of Assessment. The current gold
standard technique for noninvasive assessment of the
endothelium is ﬂow-mediated dilatation (FMD) using ultra-
sound. This method is based on the vasodilatation initiated
by the reactive increase in blood ﬂow in the brachial artery
(or other conduit arteries) following a 5-minute period of
forearm ischemia mediated by suprasystolic inﬂation of a
blood pressure cuﬀ on the arm. The resultant hyperemia
following cuﬀ release causes an increase in local shear
stress in the vessel which stimulates the endothelium to
generate and release NO, which activates guanylyl cyclase
to produce cyclic GMP in vascular smooth muscle which
causes relaxation and dilatation of the artery [5, 15]. The
changes in blood ﬂow and vessel diameter can be assessed by
imaging the brachial artery and measuring blood ﬂow with
high-resolution 2D ultrasound and Doppler interrogation
(Figure 1). It is also important to assess endothelium-
independent vasodilatation for comparison, which reﬂects
smooth muscle function, using the NO donor glyceryl
trinitrate (GTN), usually administered sublingually.
A technically demanding technique and initially expen-
sive to set up is FMD which is normally used in the research
laboratory where it has been demonstrated to have good
reproducibility [16]. However, it can also be used with
care in large epidemiological studies and has an expanding
role in clinical trials [17–20]. Some diﬀerences in tech-
nique and controversies remain regarding the most robust
methodology for FMD. Both cuﬀ position and duration
of the occlusion period can aﬀect the reactive hyperemic
stimulus. If the occlusion cuﬀ is positioned above the
ultrasound probe, making the whole arm ischemic including
themeasuredarterialsegment,alargerdilatationofthevessel
is seen than when the cuﬀ is placed on the forearm distal to
the study segment [15, 21]. A cuﬀ occlusion of 15 minutes
also causes a larger hyperemic response than of a 5-minute
period [22]. Thus, both proximal cuﬀ positioning and
longer occlusion periods may not speciﬁcally represent NO-
mediated endothelium-dependent vascular function [15,
23]. In contrast, a more distal positioning of the cuﬀ and
using a 5-minute occlusion period have been demonstrated
to induce NO-mediated vasodilatation, although there is still
some debate over this matter [15, 22, 24–26]. Another area
of current interest is how to interpret and adjust for the
reactive hyperemic stimulus. Previously, only the maximal
reactive hyperemic response was typically reported (if at all),
but more recently it has been recommended that the impact
ofthechangeinshearstress,representedasshearrate,should
be considered over the entire period of reactive hyperemia
using the integral of shear rate over time (AUC) [27]. Eﬀorts
have been made to reduce the variability in the methodology,
which can limit comparison of the results from diﬀerent
FMD studies [28–31].
Other methods of assessing peripheral vasomotor func-
tion involve the administration of agents such as the
β2 adrenergic receptor agonist salbutamol, which can beCardiology Research and Practice 3
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Figure 1: Setup and representative data for ultrasound evaluation of brachial FMD. (a) A sterotatic clamp with micrometer adjustment is
used to hold the ultrasound probe. The occluding cuﬀ is positioned just below the elbow. (b) Doppler trace showing ﬂow velocity proﬁle
during early reactive hyperemia. (c) B-mode image of brachial artery demonstrating selection of region of interest and edge-detection
analysis with Brachial analyzer software package. (d) Brachial artery diameter proﬁle during FMD protocol as measured using brachial
analyzer the software package (0-1 minute baseline, 1–6 minutes cuﬀ up, 6–11 minutes response to reactive hyperemia (FMD)).
administeredviaaninhalerorIVinfusionanddoesnotaﬀect
bloodpressureatstandardclinicaldoses[32–34].Salbutamol
stimulates the release of NO from the endothelium via
vascular endothelial β2 receptor activation. This reduces
arterial tone and stiﬀness, which can be measured in the
peripheral waveform with either pulse wave analysis (PWA)
by applanation tonometry at the radial artery or pulse
contour analysis (PCA) with digital photoplethysmography
(Figure 2). Assessment of the changes on the central aor-
tic waveforms can also be measured by using a transfer
function which has been validated only in adults. Despite
these techniques’ relative simplicity and low cost, there are
practical concerns regarding reproducibility compared with
FMD especially if using PCA and in children [16].
Additionally, little correlation was observed between
FMD and results with these techniques, implicating distinct
pathophysiological inﬂuences at diﬀerent levels of the vascu-
lature requiring further evaluation [16].
Pulse amplitude tonometry (PAT) is another technically
straightforward technique, which uses the same stimulus
as FMD. The Endo-PAT system uses a ﬁngertip probe to
measures changes in arterial pulsatile volume. Recordings
are made simultaneously in the right and left index ﬁngers
so providing an internal control. As a measure of reactive
hyperemia, similarly provoked by a 5-minute period of
forearmischemia,theRH-PATindexiscalculatedastheratio
of the average amplitude of the PAT signal over a 1-minute
time interval starting 1min after cuﬀ deﬂation, divided by
the average amplitude of the PAT baseline (Figure 3). RH-
PAT index values from the study arm are normalized to the
control arm. Reproducibility has been demonstrated to be
similar to that of FMD, and mechanistically the vasodilation
is mediated at least in part by NO [35, 36]. However, it is not
entirely NO dependent, and there is likely to be an important
interaction with the autonomic nervous system that may
confound interpretation of the results from a speciﬁc
endothelial perspective. Another limitation of the technique4 Cardiology Research and Practice
Figure 2: An example of the eﬀect of salbutamol and glyceryl
trinitrate (GTN) on the radial waveform in a single individual.
The second systolic peak, obvious at baseline, is attenuated by
salbutamol and almost completely abolished following GTN.
Augmentation index (AIx), calculated as the ratio of the pulse
pressureatthesecondsystolicpeaktothatattheﬁrstsystolicpeakis
used to quantify the changes in the waveform. BP = blood pressure.
Printed with permission from [33].
is the inability to take into account the impact of auto-
nomic inﬂuences on endothelium-independent response to
systemic GTN due to lack of a simultaneous unexposed
control arm.
Endothelial function can also be assessed using pulse
wave velocity measurement. Arterial stiﬀness in the brachial
artery reﬂects both arterial wall composition and smooth
muscle tone. In response to a reactive hyperaemic stimulus,
which increases shear stress and stimulates endothelial NO
release, pulse wave velocity (PWV) slows due to the resultant
dropinsmoothmuscletone[37].Thissimpletechnique,ﬁrst
developed by Naka et al. uses two cuﬀs, one placed at the
wrist and one on the upper arm, to assess PWV in the arm;
the reactive hyperaemic stimulus is induced by wrist cuﬀ
occlusion. An inverse relationship has been shown between
PWV slowing and FMD using another method measuring
carotid-radial PWV [38]. However these approaches still
require further reﬁnement and validation, but their relative
simplicity is appealing for their potential application in
larger-scale studies.
Increases in skin blood ﬂow in the distal forearm
following local thermal hyperemia, reactive hyperaemia,
or iontophoretic application of endothelial agonists can
be measured using the laser Doppler ﬂowmetry: allowing
assessment of cutaneous microvascular endothelial function.
However, local changes in blood ﬂow are only in part due to
NO, with prostanoids also mediating some of the response
[39, 40]. Reproducibility for this technique has been shown
to be similar to that of FMD [41].
In conclusion FMD is the current gold standard and
most used method for noninvasive assessment of endothelial
vasomotor function. There are other less expensive and
technically simpler methods emerging, most notably,s Endo-
PAT, but questions remain regarding which pathways are
being assessed by these techniques as responses may not
correlate with FMD or are not fully attenuated by NO
inhibition. Furthermore, some of these techniques may
also be less sensitive and reproducible than FMD, thus
necessitating larger study cohorts.
4. ClinicalApplicationof Endothelial
Function Testing
How Do We Apply the Methodology in Clinical Studies,
What Can It Show Us and How Do the Results Enhance
Our Understanding of Vascular Biology, Atherosclerosis and
CVD?
4.1. Role of Endothelial Function in Case-Control and Cohort
Studies. Endothelial function testing was initially a research
laboratory-based technique in relatively small case-control,
cross-sectional, and interventional studies. However, with
theimprovementintechnologyallowingsmallerandcheaper
equipment and the development of semiautomated anal-
ysis techniques, endothelial function testing is now being
included in large prospective cohort studies. Indeed, Donald
et al. have recently shown that FMD can be measured with
high reproducibility in a large pediatric cohort of just under
8,000 participants, the Avon Longitudinal Study of Parents
and Children (ALSPAC) [20].
One of the ﬁrst cohort studies to measure endothelial
function was the Cardiovascular Health study which assessed
FMD in 2792 72–98-year olds between 1997 and 1998. This
study was primarily investigating factors related to the onset
and course of coronary heart disease and stroke, but also
evaluated the prognostic ability of FMD to predict cardio-
vascular events in older adults [9]. Another cohort study,
the Fireﬁghters and Their Endothelium (FATE), was inten-
tionally set up to assess the relationship between endothelial
function, emerging risk factors, and atherosclerotic vascular
disease in 1600 middle-aged ﬁre ﬁghters [42]. Other estab-
lished longitudinal studies have also incorporated endothe-
lialfunctiontestingintotheirscreeningvisits.Betweenthem,
these cohorts cover a wide range of ages and exposures from
prenatal and early life (ALSPAC) through later childhood
into adulthood (Young Finns’ and Framingham’s oﬀspring
studies) [20, 43, 44]. From a practical perspective, it may
not always be appropriate or logistically possible to admin-
ister GTN to study endothelium-independent vasodilatation
within these studies, which can limit the speciﬁcity of the
observations.
4.2. Insights and Opportunities from Cohort Studies. Cardio-
vascular risk factors have long been associated with dimin-
ished endothelial function, conﬁrmed more recently in the
larger cohort studies [45, 46]. In those with impaired FMD,
risk factor burden is associated with increased intima-media
thickness, an important subclinical marker of atherosclerosis
[47]. Not all associations, however, have been consistently
replicated in cohort studies, for example, the relationship
between attenuated endothelial function and elevated CRP
found in small cross-sectional studies [48–51]. However,
FMD is diminished in children with acute and recent minor
infections [52].
Theprospectivenatureofthesestudiesallowsresearchers
to look at the potential impact of earlier risk factor expo-
sure on contemporary endothelial function. For example,
childhood blood pressure was demonstrated to be predictiveCardiology Research and Practice 5
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Figure 3: Diagram of the Endo-PAT set-up (a). (b) Representative traces from both the study and control arms showing the changes on the
pulse amplitude after a 5-minute period of occlusion (printed with permission of Itamar Medical).
of endothelial dysfunction independent of presence and
levels of other risk factors in adult life [53]. Associations
found in cross-sectional analyses can also be followed up
prospectively in the same cohort. For example, asymmetrical
dimethylarginine (ADMA) was inversely correlated with
FMD and subsequently found to predict FMD six years later
[54, 55].
The prognostic ability of endothelial function testing
can also be examined in prospective cohorts. Endothelium-
dependent dilatation has been consistently shown to be
signiﬁcantly associated with progression of subclinical dis-
ease and incident clinical cardiovascular events in several
studies [9, 56–58]. Although this association suggests a
causally important inﬂuence on the pathogenesis of arterial
disease, this alone is insuﬃcient evidence to justify the use
of endothelial function testing in routine clinical practice
and data suggesting incremental predictive value, ideally
with regard to improved ability of the results of such a
test to reclassify the risk of an individual. Yeboah et al.
demonstrated an overall 29% correct reclassiﬁcation of
subjects into low-, medium-, and high-risk groups with the
addition of FMD to the Framingham Risk Score (FRS) in
comparison to classiﬁcation by FRS alone [59]. However, a
more recent study found that only forearm resistance vessel
endothelial function, and not FMD, was associated with 5-
year risk of cardiovascular events [60]. It is important to
note that in the latter study, the coeﬃcient of variation
for FMD was very high (29%) which may have limited
the ability of the researchers to detect modest but impor-
tant associations. This highlights very important practical
concerns regarding the suitability of endothelial function
testing for use in routine practice. The technical complexity
of clinical endothelial function testing protocols together
with the inherent physiological variability of endothelium-
dependent vasodilatation under nonstandardized conditions
means that such approaches are less practically suited for
wider routine clinical use outside of the carefully controlled
environment of a specialist vascular laboratory and currently
remain predominantly in the research domain.
FDA approval has been granted for the use of the
EndoPAT device for noninvasive detection of patients with
coronary endothelial dysfunction following a small study
of 94 subjects with chest pain who underwent invasive
coronary angiography and endothelial function testing [61].
In this cohort, an EndoPAT index threshold of 1.67 pro-
vided a sensitivity of 82% and a speciﬁcity of 77% for
coronary endothelial dysfunction which may help guide the
management of challenging patients with chest pain and
angiographically unobstructed coronary arteries but cannot
justifywiderclinicalapplicationofthistechnologyatpresent.
4.3. Role of Endothelial Function in Intervention Studies.
Endothelial function has increasingly become an attractive
endpoint for clinical studies. Indeed it is possible to detect
changes in endothelial function relatively quickly in compar-
ison to other longer-term endpoints such as changes in the
carotidorcoronarywallandoccurrenceofclinicalcardiovas-
cular events. It can also provide the opportunity to evaluate
potential “pleiotropic” inﬂuences of drugs. For example,
statins have been shown to improve endothelial function
prior to and independent of their eﬀects on the lipid proﬁle
[62, 63]. Other pharmacological interventions such as renin-
angiotensin system antagonists, calcium channel blockers,
antiplatelet drugs, and angina treatments (ranolazine) have
also been shown to have beneﬁcial eﬀects on endothelial
function in addition to their primary actions [19, 64–
67]. However, results from such studies are not always
consistent in eﬀect and results may vary between agents
and according to the vascular bed studied. For example, in
the BANFF study, FMD only improved after treatment with
quinapril and not enalapril or losartan, whilst in another
study cilazapril did not signiﬁcantly improve endothelial
function in the peripheral resistance vessels [19, 68]. Thus,
it is important to account for the potential heterogeneity
of endothelial biology when interpreting the results of
clinical interventions. These issues have been reviewed
in greater depth elsewhere [18, 69]. Nonpharmacological
interventions such as Omega 3 supplements and exercise
havealsobeenshowntoenhanceendothelialfunction,which
may in part account for their prognostic beneﬁts [70–73].
Study methodology is of course critical in the setting of
interventional studies. The study protocol and equipment
must be standardized, and observers should be trained to
a high level of quality and reproducibility [74]. Having
proven itself as an endpoint in intervention studies FMD
is now being used as an endpoint in drug development
trials(e.g.,Dal-Vessel)inordertoprovidevaluablebiological6 Cardiology Research and Practice
insights at a relevant stage of the drug’s clinical development
[17]. Although a positive impact on endothelial function
would not be an essential for further investment, an adverse
outcome might prompt more cautious progression. Indeed,
one might speculate that had a clinical endothelial function
study been conducted at an earlier stage of the Torcetrapib
developmentprogram,anadverseendothelial “signal” might
have been detected at that point prompting a more cautious
evaluation of the situation-given what we now know about
the adverse impact of this agent on blood pressure and the
renin-angiotensin system.
4.4. Endothelial “Stress Testing”: Opportunities to Gain
Additional Insights into Vascular Pathophysiology. Recently,
several experimental clinical models of acute endothelial
dysfunction have been developed which allow exploration of
endothelial behaviour in response to relevant, acute patho-
physiological stimuli. These include ischemia reperfusion,
inﬂammation, and acute psychophysiological stress. Appli-
cation of these models either to explore drivers of disease
progression and destabilization or to develop strategies to
protect the cardiovascular system against these pathophysio-
logical inﬂuences is still at an early stage but clearly has great
potential [75–80].
5. Conclusion
The endothelium has an important inﬂuence on the devel-
opment of atherosclerosis, and the assessment of its function
aﬀords a valuable insight into disease processes in the
arterial wall. This has been exploited in a wide range of
clinical situations and has more recently been used to good
eﬀect in large prospective cohort studies. It is important to
emphasizethatendothelialdysfunction,althoughimportant,
is only a component of the pathophysiological process of
atherogenesis. For example, inﬂammatory, proliferative, and
thrombotic pathways acting independently of the endothe-
lium also have important inﬂuences on plaque development,
destabilization, and clinical sequelae. Unfortunately, the
endothelium’s inherent physiological sensitivity and com-
plexity of some of the assessment methodologies make it
a less suitable parameter to guide routine clinical practice,
but it remains a core component of the clinical vascular
research technique portfolio. Indeed, results from endothe-
lial function testing provide insightful short- to medium-
term outcome measures for detailed mechanistic vascular
studies and early-phase clinical trials.
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